Brought to you by 
La Jolla acquires GliaMed’s regenerative immunophilin ligands; returns rights shortly after
03 Jan 2022
Executive Summary
Cell reprogramming biotech GliaMed Inc. has sold its regenerative immunophilin ligand (RIL) program to La Jolla Pharmaceutical Co. (formerly focused on immune diseases). The deal includes patents and patent rights, know-how, regulatory registrations, raw materials, study drug supplies, and contractual rights.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Intra-Biotech Deal
- Product Purchase
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
La Jolla acquires GliaMed’s regenerative immunophilin ligands; returns rights shortly after
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice